Get the Stockscreener App
2.37
0.42%
0.01
After Hours:
2.35
-0.02
-0.84%
Armata Pharmaceuticals Inc stock is traded at $2.37, with a volume of 12,049.
It is up +0.42% in the last 24 hours and down -3.27% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$2.36
Open:
$2.34
24h Volume:
12,049
Relative Volume:
1.46
Market Cap:
$85.75M
Revenue:
-
Net Income/Loss:
$-59.51M
P/E Ratio:
-2.1545
EPS:
-1.1
Net Cash Flow:
$-55.09M
1W Performance:
+0.42%
1M Performance:
-3.27%
6M Performance:
-43.30%
1Y Performance:
-21.00%
1-Day Range:
$2.21
$2.37
1-Week Range:
$2.19
$2.39
52-Week Range:
$1.90
$4.48
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
New player in RNA manufacturing: Aurora Biosynthetics launches in Australia - Australian Manufacturing
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 11.1% in August - MarketBeat
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Quantisnow
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in August - MarketBeat
Armata Pharmaceuticals Updates Progress and Corporate Presentation - TipRanks
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - Longview News-Journal
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - PR Newswire
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - MSN
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 12.9% in July - MarketBeat
Dr. Deborah Birx Is Now The CEO Of Armata Pharmaceuticals - KossyDerrick
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC Wainwright - Defense World
HC Wainwright Brokers Raise Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - Defense World
HC Wainwright Analysts Boost Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - MarketBeat
Armata Pharmaceuticals' (ARMP) Buy Rating Reiterated at HC Wainwright - MarketBeat
Armata Pharmaceuticals Welcomes David House as New SVP of Finance - TipRanks
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - Quantisnow
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - PR Newswire
ARMPArmata Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - InvestorPlace
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - StockTitan
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - PR Newswire
10 Best Healthcare Stocks to Invest In (August 2024) - Securities.io
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8% - MarketBeat
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PR Newswire
Innoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-Off - MSN
Armata Pharmaceuticals Adjusts Executive Compensation By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Adjusts Executive Compensation - Investing.com
Bacteriophage Therapy Market Future Business Opportunities - openPR
Staphylococcus aureus Bacteremia Treatment Market 2032: FDA - openPR
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):